| Name | Title | Contact Details |
|---|
What`s best for each patient drives our business. Through Center for Diagnostic Imaging`s national network, including Insight Imaging, we partner with healthcare providers to do what we do best — manage and deliver high-quality medical imaging (i.e. MRI, PET/CT, etc.) and related services (i.e. injections for pain) to enhance patient care. CDI offers the highest quality of care through a network of outpatient imaging centers and mobile facilities in more than thirty states. Headquartered in Minneapolis, Minnesota; the organization serves more than one million patients a year through a diverse set of customers including healthcare providers, managed care organizations, hospitals, health systems and payors (government and third party). Our local providers and partners are connected through CDI`s large network to other clinical providers and staff across the country. Through CDI`s sophisticated network, our partners access best practices and have the ability to consult with other specialized physicians, when needed, to improve patient care and outcomes. Being a national provider that is locally focused helps CDI provide each patient with the best of both worlds: individualized local patient care and extensive healthcare expertise.
Dionex Corporation (Dionex) designs, manufactures, markets, and services analytical instrumentation, related accessories, and chemicals. Its products are used to analyze chemical substances in the environment and in a range of industrial and scientific
LifeStyles Condoms is a Red Bank, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Proflex Corp is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, accurate single-use device. MY01. The simple solution to a dangerous problem.